Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

<div>Radiotherapy combined with anti-PD-L1 and anlotinib achieved the best antitumor activity. (a) Schematic showing schedules of radiotherapy, anlotinib, and anti-PD-L1. (b–e) Responses of the subcutaneous tumors in different treatment groups. CTRL: control; RT: radiotherapy; IO: immunotherapy; AN: anlotinib.</div>

Oxidative Medicine and Cellular Longevity

fig2

Figure 2

Figure 2: Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer 

Figure 2 | Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer 